Varenicline and Bupropion for Alcohol Use Disorder
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The COMB study is a randomized double-blind placebo-controlled multicenter trial in Sweden on
the efficacy of varenicline and bupropion, in combination and alone, for treatment of alcohol
use disorder (AUD).
Study design overview: A 13-weeks (91 days) multicenter clinical trial with four parallel
groups. 95 subjects per treatment arm will be randomized into the study. 380 subjects with
AUD will be randomized in total.